Article

Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study

2023-01-18

Abstract excerpt

<h4>Background</h4> Cutaneous immune-related adverse events (cirAEs) occur in up to 40% of immune checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival remains unclear. <h4>Objective</h4> To investigate the association of cirAEs with survival among ICI recipients. <h4>Methods</h4> ICI recipients were identified from the Mass General Brigham healthcare system (MGB) and Dana-Farber...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4c09d284-6887-5bd4-98c2-c0d9996bb69f
DOI: 10.1101/2023.01.16.23284635

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studyDOI 10.1101/2023.01.16.23284635Read

Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective ReviewSemantic proximity Read

Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort StudySemantic proximity Read

Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.Semantic proximity Read

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse eventsSemantic proximity Read

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity Read

Prediction and treatment of skin adverse reactions related to inhibitors at immune checkpointsSemantic proximity Read

Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.Semantic proximity Read

A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.Semantic proximity Read

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read

Dermatologic adverse events associated with targeted therapies for melanoma.Semantic proximity Read

A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA’s adverse events reporting systemSemantic proximity Read